SBI-183
Based on 1 Customer Validation
SBI-183 is an orally active inhibitor of QSOX1 (Kd: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.8%
- CAS No.: 625403-59-0
- Formule: C18H20N2O2
- Masse moléculaire:296.36
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cancer Compound Library
HY-L025
-
Orally Active Compound Library
HY-L061
-
Anti-Breast Cancer Compound Library
HY-L074
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Activité biologique
SBI-183 (6.25-50 μM, 15 min) inhibits the enzymatic activity of rQSOX1 in a dose-dependent manner[1].
SBI-183 inhibits proliferation of tumor cells, but does not kill fibroblasts or rapidly proliferating PBMC (0.625-20 μmol/L, 5 days), inhibits viability of 786-O, RCJ-41T2, and MDA-MB-231 with IC50s of 4.6 μM, 3.9 μM, and 2.4 μM, respectively (0.076 nM-40 μM, 72 h)[1].
SBI-183 (2.5-20 μM, 4-8 days) inhibits tumor invasion in both 2D and 3D models of 786-O, RCJ-41T2, MDA-MB-231, A549 and MIA PaCa2 dose-dependently[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:786-O, RCJ-41T2, MDA-MB-231, A549 和 MIA PaCa2
-
Concentration:0.625, 1.25, 2.5, 5, 10, 20 μM
-
Incubation Time:5 days
-
Result:Inhibited the growth of each tumor cell in a concentration-dependent manner.
-
Cell Line:786-O, RCJ-41T2, MDA-MB-231, A549 和 MIA PaCa2
-
Concentration:2.5, 5, 10, 20 μM
-
Incubation Time:4, 6, 8 days
-
Result:Reduced invasion through Matrigel in each cell line.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human xenograft mouse models of renal cell carcinoma (786-O and RCJ-41T2)[1]
-
Dosage:400 μg/mouse/day (786-O); 100 mg/kg (RCJ-41T2)
-
Administration:Oral gavage (p.o.)
-
Result:Inhibited the growth of 786-O and RCJ-41T2 in vivo.
Reduced laminin-α4 deposition in RCJ-41T2 mouse xenografts.
Chemical Information
-
CAS No. 625403-59-0
-
Appearance Solid
-
Masse moléculaire 296.36
-
Formule C18H20N2O2
-
Color White to off-white
-
SMILES
O=C(C1=CC(OC)=CC=C1)NC2=CC=C(N3CCCC3)C=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz